Hyperhidrosis Treatment Market Continues to Grow as Major Pharmaceutical Company Allergan receives the U.S. FDA clearance for its BOTOX indicated for hyperhidrosis

 

 

Hyperhidrosis or excessive sweating of the skin or axillary area in the general population is a common and very embarrassing problem. Sweating problems are more common in men than in women, although there are some cases of women being affected too. The main causes for sweating problems are an overactive sympathetic system and/or overstimulated sweat glands. Sweating has two types, primary hyperhidrosis, and secondary hyperhidrosis. In primary hyperhidrosis, it's usually caused by the genetic condition hyperhidrosis. In secondary hyperhidrosis, it's normally caused by environmental factors such as extreme hot or cold weather conditions. Thoracic surgery is another method of treating hyperhidrosis. In Thoracic surgery, excess sweat glands are removed or destroyed. This is done by cutting or cauterizing the nerves that supply the sweat to the sweat glands. The sweat gland then ceases to function effectively.

Increasing prevalence of secondary hyperhidrosis is expected to drive growth of the global hyperhidrosis treatment market during the forecast period. According to the National Institutes of Health, in 2016, there was around 4.8% prevalence of hyperhidrosis in the U.S., which accounted for around 15.3 million people. According to the same source, of these 15.3 million, around 70% report severe excessive sweating in at least one body area. Hyperhidrosis treatment includes specialized medications to reduce and eventually curb excessive sweating from hands, feet, armpit, and facial area. Hence, such a massive prevalence of secondary hyperhidrosis is expected to drive growth of the global hyperhidrosis treatment market during the forecast period. Furthermore, increasing disease awareness combined with the advent of novel therapies is expected to boost the global hyperhidrosis treatment market growth over the forecast period. Besides, continuous research and development activities by key market players are expected to boost the global hyperhidrosis treatment market growth over the forecast period.

However, the side effects of hyperhidrosis drugs such as mild itching, severe burning, allergic reactions, and swelling are expected to restrain growth of the global hyperhidrosis treatment market during the forecast period. Among regions, North America is expected to hold a dominant position in the global hyperhidrosis treatment market during the forecast period. This is owing to increased rate of hyperhidrosis combined with the presence of robust healthcare facilities across the region. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period. This is owing to rising awareness regarding hyperhidrosis combined with a surge in incidences of anxiety and depression in the region.

Key players operating in the global hyperhidrosis treatment market TheraVida, Allergan, Dr. August Wolff GmbH, Brickell Biotech, Inc., Ulthera, Inc., Dermira, Inc., Revance Therapeutics, Inc., and GlaxoSmithKline plc.

For instance, in July 2020, Allergan plc received the U.S. Food and Drug Administration (FDA) approval for BOTOX indicated for the treatment of hyperhidrosis and 10 other therapeutic indications.